Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myelodysplastic Syndrome (MDS) - High and Intermediate Risk”

29 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 29 results

Early research (Phase 1)Study completedNCT00807677
What this trial is testing

Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous Leukemia+9 more
Millennium Pharmaceuticals, Inc. 31
Large-scale testing (Phase 3)Ended earlyNCT04266301
What this trial is testing

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Novartis Pharmaceuticals 530
Testing effectiveness (Phase 2)Ended earlyNCT03946670
What this trial is testing

MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 127
Testing effectiveness (Phase 2)Ended earlyNCT00185679
What this trial is testing

Haploid Allogeneic Transplant Using the CliniMACS System

Who this might be right for
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk FactorsChronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic PhaseMyelodysplastic Syndrome (MDS) - High and Intermediate Risk+2 more
Ginna Laport 13
Testing effectiveness (Phase 2)Study completedNCT00439673
What this trial is testing

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Who this might be right for
Myelodysplastic Syndromes
Gruppo Italiano Malattie EMatologiche dell'Adulto 62
Testing effectiveness (Phase 2)Study completedNCT01873703
What this trial is testing

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Helsinn Healthcare SA 102
Testing effectiveness (Phase 2)WithdrawnNCT00867061
What this trial is testing

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)Study completedNCT01980056
What this trial is testing

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Who this might be right for
Myelodysplastic Syndrome
Weill Medical College of Cornell University 10
Early research (Phase 1)Study completedNCT05048498
What this trial is testing

Pharmacokinetics, Tolerability and Safety of NEX-18a

Who this might be right for
Myelodysplastic Syndromes (MDS)Chronic Myelomonocytic Leukemia (CMML)Acute Myeloid Leukemia (AML)
Nanexa AB 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT02935361
What this trial is testing

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
University of Southern California 33
Testing effectiveness (Phase 2)UnknownNCT00838240
What this trial is testing

Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia

Who this might be right for
LeukemiaMyelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC 114
Early research (Phase 1)WithdrawnNCT03057990
What this trial is testing

Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes
Montefiore Medical Center
Testing effectiveness (Phase 2)Study completedNCT02018926
What this trial is testing

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Who this might be right for
Myelodysplastic Syndrome
Mirati Therapeutics Inc. 18
Testing effectiveness (Phase 2)Ended earlyNCT04878432
What this trial is testing

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 39
Early research (Phase 1)Ended earlyNCT01003678
What this trial is testing

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

Who this might be right for
Myelodysplastic Syndrome
Roswell Park Cancer Institute 4
Testing effectiveness (Phase 2)Study completedNCT00744536
What this trial is testing

Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicAngiogenesis
Sunnybrook Health Sciences Centre 20
Early research (Phase 1)Study completedNCT03516591
What this trial is testing

AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndrome (MDS)
Amphivena Therapeutics, Inc. 14
Large-scale testing (Phase 3)Active Not RecruitingNCT05883956
What this trial is testing

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, Chronic+1 more
Otsuka Australia Pharmaceutical Pty Ltd 13
Large-scale testing (Phase 3)Ended earlyNCT02158936
What this trial is testing

Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Thrombocytopaenia
Novartis Pharmaceuticals 356
Testing effectiveness (Phase 2)Study completedNCT03433781
What this trial is testing

A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

Who this might be right for
Myelodysplastic Syndromes
NYU Langone Health 4
Load More Results